GLP-1 related substance testing sits on a regulatory foundation that surprises analysts who expect a biologics framework. Because semaglutide, liraglutide, and tirzepatide are synthetic peptides rather than recombinant proteins, their impurities are controlled as drug-substance impurities under ICH principles, sharpened by guidance written specifically for synthetic peptides. Getting that framework right shapes the specification, the qualification strategy, and even which application pathway a generic can use.
Key Takeaways |
|
Synthetic Peptide or Biologic? Why the Distinction Governs Everything
The first regulatory question for any GLP-1-related substance program is also the most consequential: is the molecule a drug or a biologic? The answer is set by size. Regulators treat peptides of forty amino acids or fewer as drugs, and semaglutide at thirty-one residues, liraglutide at thirty-one, and tirzepatide at thirty-nine all sit comfortably on the drug side of that line. They are therefore controlled as chemically synthesized drug substances, not as recombinant biologics.
That classification carries direct numeric consequences. Under FDA guidance written specifically for highly purified synthetic peptides, peptide-related impurities at or above 0.10 percent of the drug substance must be identified, and any new peptide-related impurity above 0.5 percent requires justification that it does not affect safety or effectiveness relative to the reference product. Those thresholds, not biologics comparability expectations, anchor the control strategy.
Working in analytical science?
Register for a FREE Separation Science account to subscribe to the Separation Science Newsletter.
This regulatory frame sits alongside the analytical picture in the overview of methods and challenges across GLP-1 peptide analysis, and it is shaped throughout by the structural complexity that makes these peptides difficult to characterize.
A GLP-1 agonist is a synthetic drug in the eyes of the regulator, not a biologic, and the control strategy follows that fact.
Which Thresholds Apply to GLP-1 Impurities?
The baseline thresholds come from the ICH impurity framework. ICH Q3A(R2) governs impurities in the new drug substance, and ICH Q3B(R2) governs degradation products in the drug product, together defining the reporting, identification, and qualification thresholds that scale with maximum daily dose. For a synthetic peptide, the FDA guidance overlays peptide-specific limits on top of that baseline, which is what makes peptide-related-substance control stricter than a small-molecule analyst might expect.
The practical effect is two layers working together. The ICH framework sets the general logic of reporting, identifying, and qualifying impurities by level, while the synthetic peptide guidance fixes the specific peptide-related impurity limits and ties them to a comparison against the reference listed drug. A defensible specification has to satisfy both.
Table 1. Impurity thresholds: ICH baseline and synthetic peptide overlay
Threshold | ICH Q3A and Q3B General Principle | Synthetic Peptide Overlay (FDA) |
Reporting | Impurities at or above the reporting threshold are reported, scaled to daily dose | Full impurity profile compared against the reference listed drug |
Identification | Impurities at or above the identification threshold are structurally identified | Peptide-related impurities at or above 0.10 percent are identified |
Qualification | Impurities above the qualification threshold are justified for safety | New impurities above 0.5 percent justified, including immunogenicity risk |
New impurity ceiling | Set case by case from the safety data | A new peptide-related impurity above 0.5 percent generally bars the abbreviated pathway |
Peptide-Related and Process-Related Impurities
Regulatory control divides impurities by origin, because the two classes raise different questions. Peptide-related impurities arise from the peptide itself and its synthesis, including deletion and insertion sequences, D-amino acid isomers, oxidation products, and deamidation variants. Process-related impurities come from the manufacturing process, including residual reagents, scavengers, protecting-group fragments, and residual solvents. The peptide-related class is the one that drives the most demanding regulatory scrutiny, because it is where immunogenicity risk lives.
This article treats those classes as regulatory categories rather than re-deriving their chemistry, which is set out in the catalog of GLP-1 impurity types and their structural origins. The regulatory point is simpler than the chemistry: every peptide-related impurity above the relevant threshold must be identified, and its safety, including its immunogenic potential, justified.
How Do You Qualify a GLP-1 Impurity?
Qualification is the process of establishing that an impurity at its proposed level is safe. For a small molecule this rests on toxicology and, where available, comparison to a reference product that already contains the impurity. For a synthetic peptide, the logic is similar but adds a comparison of the full impurity profile against the reference listed drug, so that the generic and the reference can be expected to behave the same way in patients.
The decisive move is the sameness comparison. If every impurity in the proposed product is present in the reference at comparable levels, qualification is straightforward. A new impurity, or one present at a higher level than in the reference, has to be justified on its own, and for a peptide, that justification reaches beyond conventional toxicology into immunogenicity.
Immunogenicity: The Peptide-Specific Dimension
Immunogenicity is what separates peptide impurity control from small-molecule impurity control. A sequence variant created during synthesis can, in principle, present a new T-cell epitope, a short sequence that binds a major histocompatibility complex molecule and provokes an immune response. The regulatory expectation is that any new peptide-related impurity is assessed for this potential, not merely for chemical purity.
The assessment is orthogonal and largely non-clinical. In silico tools predict major histocompatibility complex binding and flag candidate epitopes, and in vitro assays then test binding and T-cell activation. A peer-reviewed case study of impurity immunogenicity in a generic peptide illustrates the approach in practice, including how a marketed peptide can show only modest clinical antidrug-antibody rates, around 2.8 percent in the reference product studied, while its impurities are still evaluated rigorously. Confirming identity by orthogonal analysis feeds directly into this work, which is why mass-spectrometry confirmation of peptide identity is a regulatory enabler and not only an analytical nicety.
For a peptide, a new impurity is not only a purity question. It is an immunogenicity question.
What Does the Generic Pathway Require?
For generic synthetic peptides, the abbreviated pathway is available but narrow. FDA guidance names a specific set of reference peptides, and liraglutide, a GLP-1 agonist, is among them, with the agency noting that the same principles may extend to others such as semaglutide. The central requirement is that the proposed product demonstrate active-ingredient sameness with the reference listed drug, supported by a side-by-side impurity profile.
Where that comparison holds, and immunogenicity risk is controlled, the abbreviated pathway is open. Where a new impurity cannot be justified, or where active-ingredient sameness or immunogenicity cannot be established, the program moves to a more demanding application pathway instead. In other words, the impurity profile does not merely populate a specification; it decides which regulatory route the product can take.
Borrowing the Biologics Characterization Toolkit
Although the governing pathway is that of a synthetic drug, the characterization expectations draw heavily on the biologics world. The toolkit codified in the ICH quality guidelines for biotechnological and biological products, known as Q6B, supplies methods that map naturally onto a complex peptide: confirmation of primary sequence and amino acid composition, assessment of higher-order structure, evaluation of oligomer and aggregation states, and measurement of biological activity.
This is the reconciliation that the original framing missed. A GLP-1 agonist is controlled as a synthetic drug under ICH Q3A and Q3B, but it is characterized with techniques borrowed from Q6B, because the molecule is too complex for sequence-blind small-molecule methods alone. Demonstrating command of both the synthetic-drug control logic and the biologics-grade characterization is what earns reviewer confidence.
How Should a GLP-1 Control Strategy Come Together?
A coherent GLP-1-related-substance strategy assembles these elements into a single, defensible package rather than treating them as separate exercises. Each draws on a different reference, but they share one logic: identify what is present, hold it to the right threshold, and justify anything new on both chemical and immunological grounds.
Table 2. Elements of a GLP-1-related substance control strategy
Element | What It Covers | Primary Reference |
Active-ingredient sameness | Demonstrating that the synthetic peptide matches the reference | FDA synthetic peptide guidance |
Impurity thresholds | Reporting, identification, and qualification limits | ICH Q3A and Q3B |
Peptide-related impurities | Deletions, insertions, isomers, and oxidation products | FDA synthetic peptide guidance |
Process-related impurities | Reagents, scavengers, and residual solvents | ICH Q3A and Q3C |
Immunogenicity risk | T-cell epitope and innate-immune assessment of new impurities | FDA synthetic peptide guidance |
Characterization | Sequence, higher-order structure, aggregation, and activity | ICH Q6B toolkit |
Analytical procedures | Orthogonal, validated related-substance methods | ICH Q2(R2) and Q14 |
What This Means for Your Lab |
Build the control strategy on the synthetic-drug framework, not a biologics template. Anchor the specification to the ICH thresholds, then layer the FDA peptide-specific limits on top, and treat every new peptide-related impurity above the threshold as both a chemical and an immunogenicity question. If a generic is the goal, run the impurity-sameness comparison against the reference early, because it determines the entire regulatory route. A single unjustified impurity above 0.5 percent can move a program off the abbreviated pathway altogether. |
This article was produced under Separation Science's AI Editorial Guidelines.
